UNITY Biotechnology Inc
Change company Symbol lookup
Select an option...
UBX UNITY Biotechnology Inc
HKXCY Hong Kong Exchanges and Clearing Ltd
TOMZ TOMI Environmental Solutions Inc
GDXD MicroSectors? Gold Miners -3X Inverse Leveraged ETNs
CWK Cushman & Wakefield PLC
NAUT Nautilus Biotechnology Inc
ZSANQ Zosano Pharma Corp
CHX ChampionX Corp
UTZ UTZ Brands Inc
POSAF POSaBIT Systems Corp
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Unity Biotechnology, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of programs targeting specific biological mechanisms implicated in diseases of aging. The Company is focused on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases, with the opportunity to explore neurology and other therapeutic areas. The Company's product includes UBX1325, UBX2089 and UBX2050. UBX1325 is an advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). UBX2089, an α-Klotho hormone drug candidate, is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications. UBX2050 is investigating fully human anti-Tie2 agonist monoclonal antibody.

Closing Price
$0.8501
Day's Change
-0.1199 (-12.36%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.02
Day's Low
0.85
Volume
(Heavy Day)
Volume:
641,046

10-day average volume:
527,599
641,046
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.